AstraZeneca Pharma India Limited (ASTRAZEN.NS)
INR 8062.25
(2.46%)
INR 8062.25
(2.46%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -5.01 Billion INR | -1.65% |
| 2022 | -4.93 Billion INR | -12.13% |
| 2021 | -4.39 Billion INR | -29.27% |
| 2020 | -3.4 Billion INR | -374.74% |
| 2019 | -716.6 Million INR | 58.64% |
| 2018 | -1.73 Billion INR | -51.99% |
| 2017 | -1.13 Billion INR | -8558.18% |
| 2016 | -13.16 Million INR | 78.77% |
| 2015 | -62 Million INR | -432.94% |
| 2014 | -11.63 Million INR | 73.57% |
| 2013 | -44.01 Million INR | -2476.86% |
| 2012 | -1.7 Million INR | 99.68% |
| 2011 | -536.5 Million INR | 37.17% |
| 2010 | -853.9 Million INR | -26.98% |
| 2009 | -672.49 Million INR | 16.27% |
| 2008 | -803.17 Million INR | 27.02% |
| 2007 | -1.1 Billion INR | -2.84% |
| 2006 | -1.07 Billion INR | -61.75% |
| 2005 | -661.6 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | 100.0% |
| 2023 Q1 | 5 Billion INR | 201.46% |
| 2023 Q4 | -5.01 Billion INR | -196.35% |
| 2023 Q3 | 5.2 Billion INR | 201.06% |
| 2023 Q2 | -5.14 Billion INR | -202.88% |
| 2023 FY | -5.01 Billion INR | -1.65% |
| 2022 Q3 | 4.69 Billion INR | 201.45% |
| 2022 Q2 | -4.63 Billion INR | -203.25% |
| 2022 Q1 | 4.48 Billion INR | 201.96% |
| 2022 FY | -4.93 Billion INR | -12.13% |
| 2022 Q4 | -4.93 Billion INR | -204.98% |
| 2021 Q2 | -3.86 Billion INR | -209.66% |
| 2021 FY | -4.39 Billion INR | -29.27% |
| 2021 Q4 | -4.39 Billion INR | 0.0% |
| 2021 Q1 | 3.52 Billion INR | 203.57% |
| 2020 Q4 | -3.4 Billion INR | -235.18% |
| 2020 Q3 | 2.51 Billion INR | 215.53% |
| 2020 Q2 | -2.17 Billion INR | -186.27% |
| 2020 Q1 | 2.52 Billion INR | 452.36% |
| 2020 FY | -3.4 Billion INR | -374.74% |
| 2019 Q3 | 2.31 Billion INR | 200.01% |
| 2019 Q2 | -2.31 Billion INR | -233.44% |
| 2019 FY | -716.6 Million INR | 58.64% |
| 2019 Q1 | 1.73 Billion INR | 200.0% |
| 2019 Q4 | -716.6 Million INR | -131.0% |
| 2018 Q4 | -1.73 Billion INR | -192.39% |
| 2018 Q2 | -1.87 Billion INR | -249.17% |
| 2018 FY | -1.73 Billion INR | -51.99% |
| 2018 Q1 | 1.25 Billion INR | 210.25% |
| 2018 Q3 | 1.87 Billion INR | 200.03% |
| 2017 Q2 | -1.51 Billion INR | -231.67% |
| 2017 Q1 | 1.14 Billion INR | 8832.77% |
| 2017 Q4 | -1.13 Billion INR | -170.23% |
| 2017 FY | -1.13 Billion INR | -8558.18% |
| 2017 Q3 | 1.62 Billion INR | 207.21% |
| 2016 Q2 | -951.9 Million INR | -223.9% |
| 2016 FY | -13.16 Million INR | 78.77% |
| 2016 Q4 | -13.16 Million INR | -101.38% |
| 2016 Q3 | 951.9 Million INR | 200.0% |
| 2016 Q1 | 768.31 Million INR | 1339.1% |
| 2015 Q2 | -713.96 Million INR | -384.62% |
| 2015 Q4 | -62 Million INR | -108.68% |
| 2015 FY | -62 Million INR | -432.94% |
| 2015 Q3 | 713.96 Million INR | 200.0% |
| 2015 Q1 | 250.84 Million INR | 2255.99% |
| 2014 Q4 | -11.63 Million INR | -102.15% |
| 2014 Q2 | -541.54 Million INR | -160.8% |
| 2014 FY | -11.63 Million INR | 73.57% |
| 2014 Q1 | 890.7 Million INR | 2123.51% |
| 2014 Q3 | 541.54 Million INR | 200.0% |
| 2013 Q2 | -716.03 Million INR | -487.71% |
| 2013 Q4 | -44.01 Million INR | -106.15% |
| 2013 FY | -44.01 Million INR | -2476.86% |
| 2013 Q1 | 184.68 Million INR | 10911.7% |
| 2013 Q3 | 716.03 Million INR | 200.0% |
| 2012 Q4 | -1.7 Million INR | 0.0% |
| 2012 Q3 | - INR | 100.0% |
| 2012 Q2 | -294.67 Million INR | 0.0% |
| 2012 FY | -1.7 Million INR | 99.68% |
| 2011 FY | -536.5 Million INR | 37.17% |
| 2011 Q4 | -536.5 Million INR | 0.0% |
| 2010 FY | -853.9 Million INR | -26.98% |
| 2009 FY | -672.49 Million INR | 16.27% |
| 2008 FY | -803.17 Million INR | 27.02% |
| 2007 FY | -1.1 Billion INR | -2.84% |
| 2006 FY | -1.07 Billion INR | -61.75% |
| 2005 FY | -661.6 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aarti Drugs Limited | 5.54 Billion INR | 190.34% |
| Albert David Limited | -278.36 Million INR | -1700.646% |
| Alembic Limited | 66.9 Million INR | 7592.438% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | -27073.593% |
| Hester Biosciences Limited | 2.29 Billion INR | 318.813% |
| Hikal Limited | 7.96 Billion INR | 162.915% |
| Ind-Swift Limited | 9.5 Billion INR | 152.715% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 4275.677% |
| Unichem Laboratories Limited | 931.91 Million INR | 637.864% |
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 229.658% |
| Bafna Pharmaceuticals Limited | 229.93 Million INR | 2279.957% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 251.94% |
| Brooks Laboratories Limited | 49.48 Million INR | 10229.213% |
| Eris Lifesciences Limited | 13.8 Billion INR | 136.305% |
| Solara Active Pharma Sciences Limited | 10.03 Billion INR | 149.966% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | -260.625% |
| Wanbury Limited | 1.1 Billion INR | 553.256% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 291.908% |
| Alkem Laboratories Limited | -1.6 Billion INR | -211.448% |
| FDC Limited | -57.75 Million INR | -8579.251% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | -76.329% |
| Gufic Biosciences Limited | 3.19 Billion INR | 256.917% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | -20.693% |
| Innova Captab Limited | 2.33 Billion INR | 314.78% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | -355.139% |
| Ipca Laboratories Limited | 11.41 Billion INR | 143.91% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 118.515% |
| Lincoln Pharmaceuticals Limited | -127.63 Million INR | -3827.076% |
| Lupin Limited | 19.38 Billion INR | 125.857% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 613.669% |
| Medico Remedies Limited | 78.67 Million INR | 6470.91% |
| Morepen Laboratories Limited | -231.17 Million INR | -2068.255% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 181.406% |
| Orchid Pharma Limited | -1.31 Billion INR | -281.509% |
| Procter & Gamble Health Limited | -2.34 Billion INR | -113.477% |
| RPG Life Sciences Limited | -364.7 Million INR | -1274.401% |
| Sigachi Industries Limited | 859.94 Million INR | 682.877% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 93.083% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 3557.428% |
| Themis Medicare Limited | 764.96 Million INR | 755.254% |
| Vaishali Pharma Limited | 119.13 Million INR | 4307.362% |
| Venus Remedies Limited | -267.7 Million INR | -1772.41% |
| Windlas Biotech Limited | -273.04 Million INR | -1735.79% |
| ZIM Laboratories Limited | 983.6 Million INR | 609.599% |
| Sakar Healthcare Limited | 790.93 Million INR | 733.735% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 235.717% |
| Divi's Laboratories Limited | -39.77 Billion INR | 87.396% |
| Mankind Pharma Limited | -1.74 Billion INR | -186.695% |
| Sequent Scientific Limited | 4.17 Billion INR | 219.954% |
| Laurus Labs Limited | 24.35 Billion INR | 120.579% |
| Neuland Laboratories Limited | -214.05 Million INR | -2241.628% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 277.671% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | -16.969% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 228.13% |
| Amrutanjan Health Care Limited | -248.79 Million INR | -1914.711% |
| Wockhardt Limited | 18.27 Billion INR | 127.435% |
| Bal Pharma Limited | 1.26 Billion INR | 496.692% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 138.817% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | -332.946% |
| Par Drugs and Chemicals Limited | -366.53 Million INR | -1267.506% |
| Caplin Point Laboratories Limited | -5.5 Billion INR | 8.992% |
| Shilpa Medicare Limited | 9.06 Billion INR | 155.267% |
| Valiant Laboratories Limited | 649.9 Million INR | 871.261% |
| Ajanta Pharma Limited | -954.9 Million INR | -424.918% |
| Aarey Drugs & Pharmaceuticals Limited | 297.57 Million INR | 1784.405% |
| Granules India Limited | 9.28 Billion INR | 153.974% |
| Medicamen Biotech Limited | 160.31 Million INR | 3226.601% |
| Syncom Formulations (India) Limited | 46.21 Million INR | 10946.857% |
| Piramal Enterprises Limited | 491.39 Billion INR | 101.02% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 115.748% |
| NATCO Pharma Limited | -5.81 Billion INR | 13.831% |
| Suven Life Sciences Limited | -1.63 Billion INR | -207.004% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 359.319% |
| Strides Pharma Science Limited | 23.25 Billion INR | 121.552% |
| Indoco Remedies Limited | 6.47 Billion INR | 177.397% |
| Alpa Laboratories Limited | 35.36 Million INR | 14274.253% |
| Lasa Supergenerics Limited | 205.79 Million INR | 2535.6% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | -432.219% |